LLY Looks 24.4% Undervalued on GF Value™ Amid Obesity Treatment Market Surge
GuruFocus News
08/31/2026 13:59
On August 31, 2026, the obesity treatment sector is witnessing accelerated competition as oral GLP-1 formulations gain market traction faster than anticipated. Eli Lilly and Co (NYSE: LLY) remains a dominant player alongside Novo Nordisk, navigating a landscape where pricing strategies and efficacy benchmarks are becoming increasingly critical
- GF Value™ verdict: LLY’s current price of $1,153.38 is approximately 24.4% below its GF Value™ of $1,524.78, indicating modest undervaluation.
- GF Score™: 91/100, reflecting strong overall financial health and operational excellence.
- Key financial signal: Despite robust institutional ownership (86.78%), insiders have been net sellers over the past 12 months, offloading shares worth $3.56 billion with no insider purchases reported.
What’s Behind the News?
The obesity treatment market is evolving rapidly, driven by the swift adoption of oral GLP-1 receptor agonists, a class of drugs that have transformed weight management paradigms. Eli Lilly and Novo Nordisk are at the forefront, leveraging their extensive pipelines and late-stage clinical trials to maintain leadership. Analysts forecast the market could potentially double by the early 2030s, underscoring the sector’s growth potential. However, rising efficacy standards and evolving U.S. drug pricing policies inject uncertainty into future profitability and valuation.
Eli Lilly and Co operates within the healthcare sector, specifically in the drug manufacturing industry. The company focuses on neuroscience, cardiometabolic diseases, cancer, and immunology, with flagship products such as Mounjaro and Trulicity driving growth. As of now, Eli Lilly commands a market capitalization of $1.03 trillion, positioning it as a major pharmaceutical powerhouse with significant influence in emerging obesity treatments
Is LLY Overvalued or Undervalued?
According to GuruFocus’ proprietary GF Value™ metric, Eli Lilly’s intrinsic value stands at $1,524.78 per share, while the stock trades at $1,153.38, implying a margin of safety of roughly 24.4%. This modest undervaluation suggests that the market may not have fully priced in the company’s growth prospects, particularly in the expanding obesity treatment segment. Investors seeking a valuation cushion could find this gap noteworthy given the company’s strong fundamentals
Examining valuation multiples, LLY’s trailing twelve months (TTM) price-to-earnings (P/E) ratio is 38.7x, which is below its five-year median P/E of 53.38x. This relative compression indicates that the stock is trading at a discount compared to its historical earnings multiple, reinforcing the GF Value™ signal. However, the forward P/E ratio is not available, limiting forward-looking valuation insights. For more on GF Value™, visit GuruFocus GF Value™
What Does LLY’s GF Score™ Tell Us?
The GF Score™ aggregates multiple dimensions of a company’s financial health, including profitability, growth, valuation, momentum, and financial strength, to provide a comprehensive quality rating. Eli Lilly’s GF Score™ of 91 out of 100 reflects exceptional performance across most categories, signaling a robust business model and operational efficiency
| Metric | Rating |
|---|---|
| GF Score™ | 91 |
| Financial Strength | 6/10 |
| Profitability | 10/10 |
| Growth | 10/10 |
| Valuation | 8/10 |
| Momentum | 3/10 |
The standout sub-ranks for Eli Lilly are profitability and growth, both scoring a perfect 10, underscoring the company’s strong earnings margins and consistent revenue expansion (31.9% revenue growth over three years, 45% earnings growth over three years). The valuation rank of 8/10 aligns with the GF Value™ assessment of modest undervaluation. However, momentum is a relative weakness at 3/10, reflecting recent stock price volatility and a 7.5% decline over the past week. Financial strength is moderate at 6/10, partly due to new debt issuance totaling $35.7 billion over three years, though the company maintains a strong Altman Z-Score of 7.61, indicating low bankruptcy risk. For further details, see the LLY stock page.
What Are Gurus and Insiders Doing with LLY?
GuruFocus tracks 25 premium gurus holding Eli Lilly shares, with 13 adding to their positions and 10 trimming stakes in recent quarters. This net positive guru activity suggests continued institutional confidence in LLY’s long-term prospects, especially given the competitive dynamics in obesity treatments. Conversely, insider activity reveals a different narrative: insiders have been net sellers over the past 12 months, offloading shares valued at approximately $3.56 billion with no insider buying reported. This divergence between institutional and insider behavior may reflect differing views on near-term valuation or liquidity preferences.
What This Means for Investors
LLY’s 24.4% undervaluation per GF Value™ combined with a stellar GF Score™ of 91/100 paints a picture of a fundamentally strong company trading below its intrinsic worth. The relatively lower P/E ratio compared to its five-year median adds further conviction to the valuation thesis. However, investors should weigh this against insider selling and sector-specific risks such as pricing pressures and intensifying competition in obesity treatments. The robust institutional guru ownership trend, unique to GuruFocus data, provides a valuable signal of sustained confidence from sophisticated market participants. For those analyzing Eli Lilly’s positioning within the evolving pharmaceutical landscape, the LLY stock page offers comprehensive insights and updated metrics.
Frequently Asked Questions
What is LLY’s GF Score™?
LLY’s GF Score™ is 91 out of 100, indicating a very strong overall financial and operational profile, with particularly high marks in profitability and growth
Is LLY overvalued or undervalued?
Based on GF Value™, LLY is modestly undervalued by approximately 24.4%, trading at $1,153.38 versus an intrinsic value estimate of $1,524.78
What is LLY’s P/E ratio compared to historical?
LLY’s trailing P/E ratio is 38.7x, which is below its five-year median P/E of 53.38x, suggesting the stock is trading at a discount relative to its historical earnings multiple
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Disclosures
I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.
